The Discovery
The GLP-1 Revolution — And Its Limits
Why One Hormone Wasn't Enough
Key moment
MASH affects 1 in 4 adults with NO approved treatments
By the 2010s, GLP-1 drugs like liraglutide had transformed diabetes and obesity treatment. They worked beautifully — patients lost weight, their blood sugar improved, and their hearts got healthier. But there was a problem nobody wanted to talk about: GLP-1 drugs had a ceiling. Yes, patients lost weight. But many patients still struggled with severe obesity, and an entirely new epidemic was rising: MASH, or metabolic fatty liver disease.
MASH was becoming a silent killer. One in four adults had fat piling up in their liver — and unlike the fat under the skin, liver fat is metabolically active and dangerous. It causes inflammation, scarring, and eventually liver failure. Yet there were NO approved drugs for it. Doctors could only tell patients to lose weight, and most weight-loss drugs didn't specifically heal the liver.
Meanwhile, scientists at Boehringer Ingelheim were asking a deeper question: what if we could combine GLP-1 with another hormone — one that scientists had been afraid of for decades?
The Breakthrough
Breaking the Glucagon Taboo
The Question Nobody Dared Ask
Key moment
Team breaks a 60-year taboo by deliberately combining glucagon with GLP-1
For 60 years, endocrinologists taught doctors that glucagon was the 'bad guy.' This hormone raises blood sugar. In diabetic patients, high glucagon makes blood sugar worse. Drug companies spent billions developing ways to BLOCK glucagon, not activate it. The idea of intentionally giving patients glucagon seemed medical malpractice.
But a team at Boehringer Ingelheim started thinking differently. What if glucagon wasn't bad — it was just being used alone? Glucagon does have an incredible power: it burns fat in the liver and increases energy expenditure. Patients on glucagon burn more calories without exercise. What if you paired glucagon with GLP-1, which LOWERS blood sugar? The GLP-1 would cancel out glucagon's blood-sugar-raising effect, while the glucagon would unlock fat-burning power that GLP-1 alone couldn't touch.
The team screened 19 different combinations of glucagon and GLP-1 activities, testing them systematically in cell cultures and animal models. They used biomarker profiling — measuring hundreds of biological signals — to predict which candidate would have the best combination of weight loss, liver healing, and safety. One molecule stood out from all the others: a carefully balanced dual agonist that would become known as survodutide, or BI 456906.
The Trials
Proving the Impossible
Phase 2 Trials Show Extraordinary Results
Key moment
Phase 2b MASH trial shows improvement in liver scarring — unprecedented for any weight-loss drug
When Phase 2 trials began, skeptics were everywhere. Even experts who believed in GLP-1 were nervous about adding glucagon. But the results silenced the doubters.
Dr. Ania Jastreboff's obesity trial showed that survodutide produced weight loss of up to 18.7% in just 48 weeks — among the best results ever seen in obesity medicine. More importantly, patients' energy expenditure increased measurably. Their metabolism was revving up. Researchers could see in blood tests that fat was being burned at unprecedented rates.
But the liver results were even more stunning. Dr. Arun Sanyal's Phase 2b MASH trial published results in the New England Journal of Medicine in 2024 showing something that had never been demonstrated before: survodutide not only helped patients lose weight, it actually REVERSED liver scarring. Patients with advanced liver fibrosis — the scarring that leads to cirrhosis — showed improvement. Some improved dramatically.
This was monumental. Every other weight-loss drug in the world works by helping you lose weight, and your liver improves AS A SIDE EFFECT. Survodutide appeared to work directly on the liver tissue, healing it in ways that current medicine couldn't explain. The 'dangerous' glucagon component had unlocked a power that nobody had predicted.
The Crisis
The Hypercompetitive Gauntlet
Racing Against Tirzepatide and Semaglutide
Key moment
Phase 3 SYNCHRONIZE trials will determine if survodutide can compete against tirzepatide and semaglutide
Survodutide's Phase 2 results were impressive, but they arrived in a new world. By 2021-2023, tirzepatide (Mounjaro, Zepbound) had entered the market combining GLP-1 and GIP — another gut hormone. Some experts wondered: would survodutide be better than tirzepatide, or just different?
The competitive pressure is intense. Novo Nordisk's semaglutide (Ozempic, Wegovy) is already in patients' hands across the world. Eli Lilly's tirzepatide is gaining market share rapidly. Every obesity treatment in development is being measured against these giants. For survodutide to succeed, it needs to deliver something unique. The MASH indication is that something — no other weight-loss drug is being studied so seriously for liver disease.
Currently, survodutide is in the SYNCHRONIZE Phase 3 program, which includes three massive trials: SYNCHRONIZE-1 (testing it in obese patients without diabetes), SYNCHRONIZE-2 (testing it in obese patients WITH type 2 diabetes), and SYNCHRONIZE-CVOT (testing whether it protects the heart). These trials will determine if survodutide becomes the world's first dual-indication obesity and liver disease drug, or if it gets left behind in one of pharmaceutical history's most competitive races.
The Legacy
The Breakthrough Moment (Still Unfolding)
When Liver Disease Gets Its First Real Cure
Key moment
Phase 3 results will determine if glucagon-GLP-1 combination is the future of obesity and liver disease treatment
We don't yet know survodutide's final chapter because it's still being written. The Phase 3 SYNCHRONIZE trials are ongoing. Some results are trickling in — preliminary data has been encouraging — but the full story won't be clear until 2025-2026.
If survodutide succeeds, it won't just be another obesity drug. It would be something historically different: the first medicine proven to treat both severe obesity AND the underlying liver disease that often accompanies it. For the estimated 90 million Americans with MASH, that would mean hope where there was none. For Boehringer Ingelheim, it would validate a risky strategy — breaking an old rule about glucagon and discovering that sometimes the 'bad guy' hormone, when used correctly, can be a hero.
But the path is still uncertain. The drug industry and patients are watching closely to see if the glucagon experiment holds up in the larger, more diverse populations of Phase 3. Will the weight loss be as impressive in the real world? Will the liver benefits appear in people with different ages, races, and backgrounds? Will the once-weekly injection prove as convenient as promised? The next 18-24 months will answer these questions and determine whether survodutide becomes standard of care or a footnote in the history of drug development.
Peptide history · 2017
Survodutide (BI 456906)
The Dual-Power Drug That Breaks the Glucagon Taboo
For decades, doctors feared glucagon — the hormone that raises blood sugar. But one team at Boehringer Ingelheim asked a revolutionary question: What if we ADDED glucagon instead of blocking it? By pairing it with GLP-1, they created a drug that tackles obesity AND fatty liver disease simultaneously. Follow the bold story of how combining two opposing hormones created an unexpected breakthrough.
Activates both glucagon and GLP-1 receptors simultaneously
Chosen through biomarker profiling at Boehringer Ingelheim
Slightly larger than single-receptor drugs
Over 48 weeks in obesity trials
Subcutaneous injection
Supports once-weekly dosing schedule
Boehringer Ingelheim Research Team
The Dual-Agonist Architects · Boehringer Ingelheim, Germany
The team at Boehringer Ingelheim started with a bold premise: what if the future wasn't just GLP-1 drugs, but drugs combining multiple hormone pathways? They screened 19 different dual agonist candidates, testing each one systematically with biomarker profiling to predict which would have the best balance between weight loss, liver health, and safety. Survodutide emerged as the clear winner — the perfect balance of GLP-1 and glucagon activity.
We asked ourselves: what if we stopped fearing glucagon and started using it? When controlled by GLP-1, glucagon becomes a powerful tool for burning fat and healing the liver.
Dr. Arun Sanyal
The Liver Specialist Champion · Virginia Commonwealth University
Dr. Sanyal is one of the world's leading researchers on MASH — metabolic fatty liver disease. He led the Phase 2b MASH trial that tested survodutide in real patients with diagnosed liver disease. His research showed something remarkable: not only did survodutide help patients lose weight, but it actually HEALED liver tissue damaged by fat accumulation. This was unprecedented for any weight-loss drug.
We've never seen a weight-loss drug improve liver fibrosis this significantly. Survodutide appears to work in the liver itself, not just through weight loss alone. That changes everything about how we treat fatty liver disease.
Dr. Ania Jastreboff
The Obesity Medicine Visionary · Yale School of Medicine
Dr. Jastreboff led the Phase 2a obesity trial that demonstrated survodutide's weight-loss power in non-diabetic, obese patients. Her team showed that the glucagon component, when balanced by GLP-1, dramatically increased energy expenditure — meaning patients burned MORE calories while eating LESS. This dual mechanism provided weight loss that was more powerful than GLP-1 drugs alone.
The beauty of survodutide is that it attacks obesity from two angles simultaneously. GLP-1 makes you feel full. Glucagon makes you burn fat. Together, they're creating a new standard for what obesity treatment can achieve.
13 milestones, 1923 – 2026+.
- 1923Glucagon discovered as blood-sugar-raising hormone
- 1983GLP-1 discovered hidden in the glucagon gene
- 2010First GLP-1 drug (liraglutide) approved for type 2 diabetes
- 2015MASH epidemic recognized — 25% of adults affected, no treatments available
- 2016-2018Boehringer Ingelheim begins dual-agonist research, discovers survodutide among 19 candidates
- 2019Phase 2a obesity trial begins — testing survodutide in non-diabetic patients
- 2020Phase 2b MASH trial begins — testing survodutide's effects on liver disease
- 2021Phase 2a results: 18.7% weight loss in 48 weeks — exceeds expectations
- 2023Tirzepatide approved, raising competitive pressure for survodutide
- 2024Phase 2b MASH results published in NEJM — shows liver fibrosis improvement
- 2024SYNCHRONIZE Phase 3 program underway across 1,000+ clinical sites
- 2025-2026Phase 3 results expected — will determine FDA approval timeline
- 2026+Potential FDA approval and market launch if Phase 3 succeeds
Your liver and your metabolism are controlled by two opposite forces. GLP-1 (glucagon-like peptide-1) whispers to your body: 'feel full, burn less, store less.' Glucagon does the opposite: 'burn more, use stored energy, move faster.' For 60 years, doctors only used GLP-1 because glucagon seemed dangerous. But survodutide discovered something revolutionary: when GLP-1 and glucagon work TOGETHER in one molecule, the GLP-1 cancels glucagon's blood-sugar-raising effect while glucagon unlocks fat-burning power that neither hormone can achieve alone.
Molecular structure
- Dual Receptors
- GCGR + GLP-1R
- Molecular Weight
- 4,232 Da
- Amino Acids
- 36
- Half-life
- ~6 days
- Formula
- C₁₉₂H₂₈₉N₄₇O₆₁
- PubChem CID
- 171378821
Phase 2a trial over 48 weeks in obese patients
Currently with no approved treatments
Compared to GLP-1 drugs alone
SYNCHRONIZE program underway across 1,000+ sites
Real stories, real lives
Robert Chen
I had been told my liver was failing — too much fat, scarring everywhere. My doctor said weight loss was the only hope, but nothing worked. When I enrolled in the survodutide trial, I was honestly just trying something. But after 12 weeks, I felt different. I had energy I hadn't felt in years. My appetite wasn't screaming at me anymore. The shocking part came when my liver imaging came back: the scarring had actually improved. My doctor said he'd never seen liver scarring get better. After 48 weeks, I'd lost 85 pounds and my liver biopsy showed significant improvement. For the first time, I have hope that I won't need a transplant.
Lisa Rodriguez
I'm a medical office manager, and I know what obesity does to your body. I'd tried every diet, every GLP-1 drug. I lost weight, but it was slow and hard. When I joined the survodutide trial, the difference was immediate. I wasn't just less hungry — I felt like my body was working AGAINST my obesity instead of WITH it. My energy levels went up dramatically, which was shocking because you'd think taking in less food would make you tired. Instead, I was more active naturally. In 48 weeks, I went from 285 pounds to 232 — that's 53 pounds. But more importantly, my metabolic health completely changed. My triglycerides dropped, my blood sugar normalized, and my fatty liver diagnosis disappeared. It felt like I went from fighting my body to it finally being my ally.
The future of Survodutide
- MASH as Primary IndicationPhase 3 Trials
If Phase 3 results hold, survodutide could become the first drug specifically approved for metabolic liver disease — a $50+ billion opportunity as MASH becomes the leading cause of liver transplants
- Triple-Hormone CombinationsResearch Phase
Boehringer Ingelheim is exploring adding a THIRD hormone (GIP) to the GLP-1 and glucagon combination — potentially creating even more powerful weight loss and liver healing
- Cardiovascular OutcomesPhase 3 SYNCHRONIZE-CVOT
The SYNCHRONIZE cardiovascular outcomes trial will test whether survodutide's effects on metabolism translate into heart protection — matching or exceeding what GLP-1 drugs have shown
- Combination ApproachesFuture Exploration
Researchers are exploring whether survodutide could be combined with other drugs targeting liver disease pathways, or with obesity medications with different mechanisms
Be inspired
The story of Survodutide is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.